Anchor Investment Management LLC Increases Stock Position in Thermo Fisher Scientific Inc. $TMO

Anchor Investment Management LLC boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 31.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,232 shares of the medical research company’s stock after acquiring an additional 1,960 shares during the quarter. Anchor Investment Management LLC’s holdings in Thermo Fisher Scientific were worth $4,127,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of TMO. ABS Direct Equity Fund LLC bought a new position in Thermo Fisher Scientific during the second quarter valued at approximately $251,000. Rench Wealth Management Inc. raised its stake in Thermo Fisher Scientific by 17.6% during the 2nd quarter. Rench Wealth Management Inc. now owns 2,906 shares of the medical research company’s stock valued at $1,457,000 after buying an additional 434 shares during the last quarter. Bouchey Financial Group Ltd. bought a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at $205,000. Van Hulzen Asset Management LLC purchased a new position in shares of Thermo Fisher Scientific in the 2nd quarter worth $260,000. Finally, MCF Advisors LLC increased its position in Thermo Fisher Scientific by 11.3% during the second quarter. MCF Advisors LLC now owns 7,978 shares of the medical research company’s stock valued at $4,003,000 after acquiring an additional 807 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on TMO. Citigroup downgraded Thermo Fisher Scientific from a “buy” rating to an “underperform” rating in a research note on Wednesday, September 9th. Barclays raised their price objective on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an “overweight” rating in a report on Friday, July 24th. Royal Bank Of Canada boosted their target price on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a “sector perform” rating in a research report on Friday, July 24th. Evercore set a $570.00 price target on shares of Thermo Fisher Scientific in a research report on Monday, July 6th. Finally, Wolfe Research assumed coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and an average target price of $624.64.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock traded up $27.26 during trading hours on Tuesday, reaching $640.88. 3,022,434 shares of the company traded hands, compared to its average volume of 2,232,038. The firm has a 50-day moving average price of $582.32 and a 200 day moving average price of $519.25. The company has a market cap of $236.96 billion, a P/E ratio of 34.47, a P/E/G ratio of 2.55 and a beta of 0.85. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. Thermo Fisher Scientific Inc. has a 12-month low of $435.27 and a 12-month high of $647.00.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. During the same period in the prior year, the firm posted $4.28 EPS. The firm’s quarterly revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.11%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction on Monday, July 27th. The stock was sold at an average price of $565.00, for a total value of $226,000.00. Following the completion of the sale, the chief operating officer owned 24,651 shares in the company, valued at approximately $13,927,815. This represents a 1.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa Britt sold 11,440 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total value of $7,014,092.80. Following the sale, the vice president directly owned 14,784 shares in the company, valued at approximately $9,064,366.08. This represents a 43.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 73,768 shares of company stock worth $44,122,820 in the last three months. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc is a global supplier of scientific equipment, laboratory services and analytical technologies. The company serves pharmaceutical and biotechnology companies, clinical laboratories, academic and government institutions, industrial businesses and other research organizations.

Its products and services include laboratory instruments, analytical systems, reagents, consumables, software and related services. Thermo Fisher also provides laboratory supplies and equipment, bioproduction solutions, genetic analysis technologies, clinical diagnostics, specialty diagnostic products and contract research and manufacturing services through its laboratory services businesses.

The company was formed in 2006 through the merger of Thermo Electron Corporation and Fisher Scientific International.